Current status of maintenance therapy for advanced ovarian cancer

Even after countered with and responding to maximal surgical and chemotherapy efforts, advanced ovarian cancer usually ultimately recurs. One strategy employed to forestall recurrence is maintenance chemotherapy, an extension of treatment following a complete response to conventional measures. Many...

Descripción completa

Detalles Bibliográficos
Autores principales: Hope, Joanie Mayer, Blank, Stephanie V
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2971701/
https://www.ncbi.nlm.nih.gov/pubmed/21072286
_version_ 1782190647687512064
author Hope, Joanie Mayer
Blank, Stephanie V
author_facet Hope, Joanie Mayer
Blank, Stephanie V
author_sort Hope, Joanie Mayer
collection PubMed
description Even after countered with and responding to maximal surgical and chemotherapy efforts, advanced ovarian cancer usually ultimately recurs. One strategy employed to forestall recurrence is maintenance chemotherapy, an extension of treatment following a complete response to conventional measures. Many agents have been studied and many more are currently under investigation in maintenance regimens. While phase III data suggest that taxane maintenance prolongs progression-free survival, no overall survival benefit has been established. This article reviews the current status of maintenance therapy for advanced ovarian cancer, including phase III evidence and new and upcoming trials.
format Text
id pubmed-2971701
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-29717012010-11-10 Current status of maintenance therapy for advanced ovarian cancer Hope, Joanie Mayer Blank, Stephanie V Int J Womens Health Review Even after countered with and responding to maximal surgical and chemotherapy efforts, advanced ovarian cancer usually ultimately recurs. One strategy employed to forestall recurrence is maintenance chemotherapy, an extension of treatment following a complete response to conventional measures. Many agents have been studied and many more are currently under investigation in maintenance regimens. While phase III data suggest that taxane maintenance prolongs progression-free survival, no overall survival benefit has been established. This article reviews the current status of maintenance therapy for advanced ovarian cancer, including phase III evidence and new and upcoming trials. Dove Medical Press 2010-08-09 /pmc/articles/PMC2971701/ /pubmed/21072286 Text en © 2009 Hope and Blank, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Hope, Joanie Mayer
Blank, Stephanie V
Current status of maintenance therapy for advanced ovarian cancer
title Current status of maintenance therapy for advanced ovarian cancer
title_full Current status of maintenance therapy for advanced ovarian cancer
title_fullStr Current status of maintenance therapy for advanced ovarian cancer
title_full_unstemmed Current status of maintenance therapy for advanced ovarian cancer
title_short Current status of maintenance therapy for advanced ovarian cancer
title_sort current status of maintenance therapy for advanced ovarian cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2971701/
https://www.ncbi.nlm.nih.gov/pubmed/21072286
work_keys_str_mv AT hopejoaniemayer currentstatusofmaintenancetherapyforadvancedovariancancer
AT blankstephaniev currentstatusofmaintenancetherapyforadvancedovariancancer

Ejemplares similares